通化東寶(600867.SH):磷酸西格列汀片獲得藥品註冊證書
格隆匯9月6日丨通化東寶(600867.SH)公佈,公司近日收到國家藥品監督管理局核准簽發的磷酸西格列汀片《藥品註冊證書》。
磷酸西格列汀是一種強效、高選擇性二肽基肽酶-4(DPP-4)抑制劑,該類藥物較傳統降糖藥物,具有不增加低血糖風險、對體重影響中性、心血管安全性良好等優勢。
近年來國內DPP-4抑制劑市場規模呈明顯上升趨勢,根據默沙東財報,2020年默沙東的磷酸西格列汀全球銷售額為33.06億美元。同樣磷酸西格列汀在國內的銷售也不斷增長。根據醫藥魔方數據顯示,中國城市公立醫院、縣級公立醫院磷酸西格列汀片(商品名:“捷諾維”)2020年銷售金額為11.72億元人民幣,2016年至2020年年複合增長率為59.69%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.